Biofrontera AG (B8FK.DE)

2.9950 0.0000 (0.00%) 收市：05:36PM CEST

Biofrontera AG

Hemmelrather Weg 201
Leverkusen 51377
Germany
49 214 87632 0
https://www.biofrontera.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 97

高階主管

名稱	頭銜	支付	行使價	出生年份
Ms. Pilar de la Huerta Martinez	CFO & Member of Executive Board	369k	無	1969
Mr. Ludwig M. Lutter	Member of the Executive Board	435.65k	無	1967
Mr. Alexander Richardson	Head of UK Sales Team	無	無	無
Dr. Matthias Naumann	Head of Sales & Marketing - Europe	無	無	無
Dr. Montserrat Foguet Ph.D.	Managing Director of Biofrontera UK Ltd.	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin. The company has a license and supply agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

公司管治

截至 無 止，Biofrontera AG 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。